Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | SVP, GLOBAL SALES AND SERVICES | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,466 |
Ending reported balance
After 2026-05-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-05-18 · Exercise / conversion · Acquired 1,024 · Balance 36,711 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-05-18 · Tax withholding · Disposed 263 · Balance 36,448 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-05-18 · Exercise / conversion · Acquired 1,473 · Balance 37,921 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-05-18 · Tax withholding · Disposed 378 · Balance 37,543 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-05-18 · Exercise / conversion · Acquired 2,416 · Balance 39,959 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-05-18 · Tax withholding · Disposed 620 · Balance 39,339 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-05-18 · Exercise / conversion · Acquired 5,551 · Balance 44,890 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-05-18 · Tax withholding · Disposed 1,424 · Balance 43,466 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,641 |
Reported balance
After 2026-05-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-18 · Exercise / conversion · Disposed 1,024 · Balance 5,641 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,209 |
Reported balance
After 2026-05-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-18 · Exercise / conversion · Disposed 1,473 · Balance 16,209 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 41,089 |
Reported balance
After 2026-05-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-18 · Exercise / conversion · Disposed 2,416 · Balance 41,089 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 127,675 |
Reported balance
After 2026-05-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-18 · Exercise / conversion · Disposed 5,551 · Balance 127,675 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter.
F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.
F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · derivative · entry 12 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,675 Underlying: Common Stock · 5,551 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · derivative · entry 11 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,089 Underlying: Common Stock · 2,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · derivative · entry 10 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,209 Underlying: Common Stock · 1,473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · derivative · entry 9 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,641 Underlying: Common Stock · 1,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,424 | $3.55 | $5,055.20 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 8 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,466 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 7 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 620 | $3.55 | $2,201.00 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,339 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 378 | $3.55 | $1,341.90 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,543 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 263 | $3.55 | $933.65 |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,448 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,024 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-26-000002 · form4-05202026_090503.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · derivative · entry 11 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,505 Underlying: Common Stock · 4,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. F7 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · derivative · entry 10 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,682 Underlying: Common Stock · 2,946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · derivative · entry 9 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,665 Underlying: Common Stock · 2,049 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 133,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · derivative · entry 8 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,226 Underlying: Common Stock · 133,226 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 70,665 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · derivative · entry 7 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,665 Underlying: Common Stock · 70,665 shares Expires 2036-03-09 F3 · derivative.exercise_date: The shares subject to the stock option shall vest over 4 years with 1/48 of the total shares underlying the stock option vesting on April 10, 2026 and each month thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,496 | $4.23 | $6,328.08 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · nonDerivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,687 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · nonDerivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 912 | $4.23 | $3,857.76 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,350 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,946 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 635 | $4.23 | $2,686.05 |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,316 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-26-000001 · form4-03122026_080302.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · derivative · entry 9 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,338 Underlying: Common Stock · 3,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · derivative · entry 8 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,628 Underlying: Common Stock · 2,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · derivative · entry 7 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,714 Underlying: Common Stock · 1,536 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 927 | $5.53 | $5,126.31 |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · nonDerivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,902 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · nonDerivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 565 | $5.53 | $3,124.45 |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,204 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 393 | $5.53 | $2,173.29 |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,559 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001991396-25-000002 · form4-11212025_121133.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · derivative · entry 9 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,963 Underlying: Common Stock · 3,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · derivative · entry 8 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,838 Underlying: Common Stock · 2,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · derivative · entry 7 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,250 Underlying: Common Stock · 1,536 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,412 | $4.06 | $5,732.72 |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · nonDerivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,416 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · nonDerivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 861 | $4.06 | $3,495.66 |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,203 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 599 | $4.06 | $2,431.94 |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,854 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022523 · form4-08202025_090849.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · derivative · entry 9 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,588 Underlying: Common Stock · 2,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · derivative · entry 8 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,048 Underlying: Common Stock · 1,473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · derivative · entry 7 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,786 Underlying: Common Stock · 1,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 942 | $2.69 | $2,533.98 |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · nonDerivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,917 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · nonDerivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 574 | $2.69 | $1,544.06 |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,443 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 399 | $2.69 | $1,073.31 |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,544 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,024 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013978 · form4-05212025_090534.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.